New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...

Learn more Collegium Pharmaceutical (COLL) should benefit from continued strength in its attention-deficit/hyperactivity disorder drugs, limited near-term generic risk for Belbuca and stable pricing ...

Collegium Pharmaceutical’s pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of ...

A new medication for chronic pain has been approved in the United States, a buprenorphine buccal film product, trade name: Belbuca. It is indicated for the treatment of chronic pain severe enough to ...